Janus Shingles Treatment Produces Encouraging Results
Posted on: Monday, 4 December 2006, 12:01 CST
Janus Pharmaceuticals has reported positive results from its study of topical ARYS-01 cream for the treatment of patients with shingles.
The study was a phase II safety, efficacy and absorption evaluation of ARYS-01 cream with the test material applied twice daily for 7 days in patients with a primary shingles episode. The results exhibited a 30% reduction in rash area in the ARYS-01 cream treatment group compared to placebo in the initial 3 days of treatment.
The active ingredient of ARYS-01 cream is sorivudine, an antiviral nucleoside analog which was originally discovered by Yamasa Corporation and is being developed as a topical formulation by Janus under a joint development agreement with Arigen of Japan. Arigen is developing ARYS-01 globally, and has several patents to cover the production method and use of the topical formulation for the treatment of shingles.
"These results provide the evidence we needed to push ahead with phase II/III trials to further validate my lifelong belief that topical ARYS-01 cream antiviral therapy can be an effective and possibly safer treatment for Herpes Zoster compared to oral antiviral therapy," stated Haruhiko Machida, chief development officer at Arigen.
Janus Pharmaceuticals will be launching a phase II/III trial in the US in the first quarter of 2007, and is targeting the new drug application for ARYS-01 cream for early 2009.
Source: Datamonitor
Related Articles
- Tranzyme Pharma Announces Positive Phase IIb Results With Its Ghrelin Agonist, TZP-101, for Postoperative Ileus (POI)
- Phase II Results of COL-144 Presented at European Headache and Migraine Trust International Congress 2008
- Fibrex Medical Report Positive Phase II Results for FX06
- Phase II Results for Low-Dose Oral Immune Tolerance Therapy (ARG201) in Systemic Scleroderma Published
- QRxPharma Releases Successful Phase 3 Study Results for 'Dual Opioid' Pain Therapy
- QuantRx(R) Biomedical Announces Positive Phase I Safety Results for CardioPET(TM), Coronary Artery Disease (CAD) Imaging Tracer for Positron Emission Tomography (PET)
- CORRECTING and REPLACING DOR BioPharma to Host Conference Call on Thursday, January 25 to Discuss Recently Published orBec(R) Phase 3 Clinical Results
- Inamed's Phase 3 Study Results for Juvederm(TM) to Be Presented at the 64th Annual Meeting of the American Academy of Dermatology
- Oxford Biomedica Plc Announces Oxford BioMedica Presents Encouraging Final Phase II Results With Trovax(R) in Colorectal Cancer at the International Colorectal Cancer Congress
- Phase I ProCord Study Results Published in the Journal of Neurosurgery: Spine, September 2005 Issue; ProCord Phase I Study Results Suggest Evidence of Safety
 |
 |
User Comments (0)
RSS Feeds